Point of Care Nano-Technology, Inc. (PCNT) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
109 AMBERSWEET ROAD DAVENPORT, FL 33897 |
| State of Incorp. | |
| Fiscal Year End | July 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 4/30/2023 Q3 | 1/31/2023 Q2 | 10/31/2022 Q1 | 7/31/2022 Q4 | 4/30/2022 Q3 | 1/31/2022 Q2 | 7/31/2015 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 7 | 6 | 3 | 0 | 4 | ||||
| Cash and cash equivalents | 7 | 6 | 3 | 0 | 4 | ||||
| Prepaid expense | 3 | 1 | 3 | ||||||
| Total current assets: | 10 | 7 | 6 | 0 | 4 | ||||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill) | 121 | 122 | 123 | ||||||
| Intangible assets, net (excluding goodwill) | 121 | 122 | 123 | ||||||
| Other undisclosed noncurrent assets | 0 | ||||||||
| Total noncurrent assets: | 121 | 122 | 123 | ||||||
| Other undisclosed assets | 100 | ||||||||
| TOTAL ASSETS: | 131 | 129 | 130 | 100 | 4 | ||||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 236 | 231 | 213 | 92 | 76 | 12 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | ✕ | 12 | |||
| Accounts payable | 236 | 231 | 213 | 92 | 76 | ||||
| Debt | 95 | ||||||||
| Total current liabilities: | 236 | 231 | 213 | 92 | 76 | 107 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed liabilities | 90 | 214 | |||||||
| Total liabilities: | 236 | 231 | 213 | 182 | 76 | 320 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (105) | (102) | (84) | (82) | (76) | (316) | |||
| Preferred stock | 0 | 0 | 0 | 0 | 0 | ||||
| Common stock | 1 | 1 | 1 | 0 | 5 | 4 | |||
| Treasury stock, value | (1) | (1) | (1) | ||||||
| Additional paid in capital | 120,192 | 120,192 | 120,192 | 120,192 | 120,187 | 119,743 | |||
| Accumulated deficit | (120,317) | (120,304) | (120,276) | (120,274) | (120,268) | (120,063) | |||
| Other undisclosed equity, attributable to parent | 20 | 10 | |||||||
| Total equity: | (105) | (102) | (84) | (82) | (76) | (316) | |||
| TOTAL LIABILITIES AND EQUITY: | 131 | 129 | 130 | 100 | 4 | ||||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 4/30/2023 Q3 | 1/31/2023 Q2 | 10/31/2022 Q1 | 7/31/2022 Q4 | 4/30/2022 Q3 | 1/31/2022 Q2 | 7/31/2015 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 100 | |||||||
| Gross profit: | 100 | |||||||
| Operating expenses | (13) | (28) | 88 | (106) | (5) | (126) | ||
| Operating income (loss): | (13) | (28) | 88 | (6) | (5) | (126) | ||
| Interest and debt expense | (5) | |||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 10 | |||||||
| Income (loss) from continuing operations: | (13) | (28) | 98 | (6) | (5) | (132) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | (28) | 98 | (6) | (5) | (132) | |
| Net income (loss): | (13) | (28) | 98 | (6) | (5) | (132) | ||
| Other undisclosed net loss attributable to parent | (100) | (9) | ||||||
| Net loss available to common stockholders, diluted: | (13) | (28) | (2) | (6) | (14) | (132) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 4/30/2023 Q3 | 1/31/2023 Q2 | 10/31/2022 Q1 | 7/31/2022 Q4 | 4/30/2022 Q3 | 1/31/2022 Q2 | 7/31/2015 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (13) | (28) | 98 | (6) | (5) | (132) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (13) | (28) | 98 | (6) | (5) | (132) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.